Universitätsklinikum Bonn

Orexa's ORE-001 Shows Significant Promise in Preventing Post-Operative Ileus in Phase 2 Trial

- Orexa B.V. reported positive interim results from its Phase 2 trial of ORE-001 for preventing post-operative ileus in patients undergoing major abdominal surgery. - The study demonstrated that patients receiving ORE-001 consumed 63% more food post-operatively, experienced first stool approximately one day earlier, and showed reduced gastrointestinal dysfunction from 21% to 6%. - Based on the promising results, Orexa will conclude the current Phase 2A trial ahead of schedule and begin preparations for Phase 2B/3 studies. - The treatment also significantly reduced extended hospitalizations due to adverse events from 31% to 7%, potentially offering substantial healthcare cost savings.